Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QGWT | ISIN: US68062P1066 | Ticker-Symbol:
NASDAQ
02.10.25 | 21:59
11,150 US-Dollar
0,00 % 0,000
1-Jahres-Chart
OLEMA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
OLEMA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur OLEMA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)23SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
► Artikel lesen
07.09.Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals32
OLEMA PHARMACEUTICALS Aktie jetzt für 0€ handeln
03.09.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)119SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
► Artikel lesen
03.09.Oppenheimer maintains Olema stock rating, sees Pfizer deal as strategic14
03.09.Oppenheimer: Pfizer-Deal positioniert Olema strategisch und könnte Bieterkampf auslösen49
03.09.Pfizer collaboration with Olema may spark future bidding war - analyst6
02.09.Olema stock jumps after new clinical trial collaboration with Pfizer12
02.09.Pfizer-Kooperation beflügelt Olema-Aktie29
02.09.Olema Pharmaceuticals, Inc. - 8-K, Current Report1
02.09.Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer426Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination...
► Artikel lesen
11.08.Olema Pharmaceuticals GAAP EPS of -$0.51 misses by $0.082
11.08.Olema Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
11.08.Olema Pharmaceuticals, Inc. - 8-K, Current Report1
11.08.Olema Oncology Reports Second Quarter 2025 Financial and Operating Results159Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line...
► Artikel lesen
04.08.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)195SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
► Artikel lesen
02.07.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)161SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
► Artikel lesen
13.06.Olema Pharmaceuticals, Inc. - 8-K, Current Report2
03.06.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)225SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
► Artikel lesen
29.05.H.C. Wainwright maintains Buy on Olema Pharma, $28 target3
28.05.Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting4
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1